Standard BioTools Inc. Amortization of Intangible Assets
Standard BioTools Inc. (LAB) reported Amortization of Intangible Assets of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-05
- Standard BioTools Inc. amortization of intangible assets for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Standard BioTools Inc. amortization of intangible assets for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Standard BioTools Inc. amortization of intangible assets for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Standard BioTools Inc. amortization of intangible assets for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Standard BioTools Inc. amortization of intangible assets for fiscal 2025 was $1.72M, a 60.54% decline from fiscal 2024.
- Standard BioTools Inc. amortization of intangible assets for fiscal 2024 was $4.35M, a 61.20% decline from fiscal 2023.
- Standard BioTools Inc. amortization of intangible assets for fiscal 2023 was $11.20M, a 2.85% decline from fiscal 2022.
- Standard BioTools Inc. amortization of intangible assets for fiscal 2022 was $11.53M, a 3.27% decline from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 3 month as first filed | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 6 month as first filed | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 9 month as first filed | Amortization of Intangible Assets 12 month | Amortization of Intangible Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $0.00 derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-05-06 | $0.00 derived: sum of 3 quarters · filed 2026-05-06 | $817.00K derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $0.00 derived: sum of 2 quarters · filed 2026-03-16 | $817.00K derived: sum of 3 quarters · filed 2026-08-05 | $1.72M 10-K · filed 2026-03-16 | ||||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $817.00K derived: sum of 2 quarters · filed 2026-08-05 | $1.72M 10-Q · filed 2025-11-04 | $2.53M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $817.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.72M 10-Q · filed 2026-08-05 | $2.53M derived: sum of 3 quarters · filed 2026-08-05 | $3.24M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $898.00K 10-Q · filed 2026-05-06 | $1.71M derived: sum of 2 quarters · filed 2026-05-06 | $2.42M derived: sum of 3 quarters · filed 2026-05-06 | $3.14M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $813.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $1.52M derived: sum of 2 quarters · filed 2026-03-16 | $2.24M derived: sum of 3 quarters · filed 2026-03-16 | $4.35M 10-K · filed 2026-03-16 | ||||
| 2024-09-30 | $711.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.43M derived: sum of 2 quarters · filed 2025-11-04 | $3.53M 10-Q · filed 2025-11-04 | $6.33M derived: sum of 4 quarters · filed 2026-03-16 | ||||
| 2024-06-30 | $716.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-15 | $2.82M 10-Q · filed 2025-08-15 | $5.62M derived: sum of 3 quarters · filed 2026-03-16 | $8.62M derived: sum of 4 quarters · filed 2026-03-16 | ||||
| 2024-03-31 | $2.11M 10-Q · filed 2025-05-06 | $4.91M derived: sum of 2 quarters · filed 2026-03-16 | $7.91M derived: sum of 3 quarters · filed 2026-03-16 | $10.91M derived: sum of 4 quarters · filed 2026-03-16 | ||||
| 2023-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $5.80M derived: sum of 2 quarters · filed 2026-03-16 | $8.80M derived: sum of 3 quarters · filed 2026-03-16 | $11.20M 10-K · filed 2026-03-16 | ||||
| 2023-09-30 | $3.00M 10-Q · filed 2023-11-07 | $6.00M derived: sum of 2 quarters · filed 2023-11-07 | $8.40M 10-Q · filed 2024-11-06 | $8.90M 10-Q · filed 2023-11-07 | $11.13M derived: sum of 4 quarters · filed 2025-03-11 | |||
| 2023-06-30 | $3.00M 10-Q · filed 2023-08-08 | $5.60M 10-Q · filed 2024-08-06 | $5.90M 10-Q · filed 2023-08-08 | $8.13M derived: sum of 3 quarters · filed 2025-03-11 | $11.03M derived: sum of 4 quarters · filed 2025-03-11 | |||
| 2023-03-31 | $2.80M 10-Q · filed 2024-05-09 | $3.00M 10-Q · filed 2023-05-09 | $5.13M derived: sum of 2 quarters · filed 2025-03-11 | $8.03M derived: sum of 3 quarters · filed 2025-03-11 | $11.23M derived: sum of 4 quarters · filed 2025-03-11 | |||
| 2022-12-31 | $2.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $5.23M derived: sum of 2 quarters · filed 2025-03-11 | $8.43M derived: sum of 3 quarters · filed 2025-03-11 | $11.53M 10-K · filed 2025-03-11 | ||||
| 2022-09-30 | $2.90M 10-Q · filed 2023-11-07 | $6.10M derived: sum of 2 quarters · filed 2023-11-07 | $9.20M 10-Q · filed 2023-11-07 | $11.62M derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2022-06-30 | $3.20M 10-Q · filed 2023-08-08 | $6.30M 10-Q · filed 2023-08-08 | $8.72M derived: sum of 3 quarters · filed 2023-08-08 | $11.82M derived: sum of 4 quarters · filed 2023-08-08 | ||||
| 2022-03-31 | $3.10M 10-Q · filed 2023-05-09 | $2.97M 10-Q · filed 2022-05-09 | $5.52M derived: sum of 2 quarters · filed 2023-05-09 | $8.62M derived: sum of 3 quarters · filed 2023-05-09 | $11.82M derived: sum of 4 quarters · filed 2023-05-09 | |||
| 2021-12-31 | $2.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $5.52M derived: sum of 2 quarters · filed 2023-03-14 | $8.72M derived: sum of 3 quarters · filed 2023-03-14 | $11.92M 10-K · filed 2023-03-14 | ||||
| 2021-09-30 | $3.10M 10-Q · filed 2022-11-09 | $6.30M derived: sum of 2 quarters · filed 2022-11-09 | $9.50M 10-Q · filed 2022-11-09 | $8.94M 10-Q · filed 2021-11-09 | $12.26M derived: sum of 4 quarters · filed 2022-11-09 | |||
| 2021-06-30 | $3.20M 10-Q · filed 2022-08-09 | $6.40M 10-Q · filed 2022-08-09 | $5.96M 10-Q · filed 2021-08-06 | $9.16M derived: sum of 3 quarters · filed 2022-08-09 | $12.16M derived: sum of 4 quarters · filed 2022-08-09 | |||
| 2021-03-31 | $2.98M 10-Q · filed 2022-05-09 | $5.96M derived: sum of 2 quarters · filed 2022-05-09 | $8.96M derived: sum of 3 quarters · filed 2022-05-09 | $11.93M derived: sum of 4 quarters · filed 2022-05-09 | ||||
| 2020-12-31 | $2.98M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $5.97M derived: sum of 2 quarters · filed 2022-03-08 | $8.94M derived: sum of 3 quarters · filed 2022-03-08 | $11.91M 10-K · filed 2022-03-08 | ||||
| 2020-09-30 | $2.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $5.96M derived: sum of 2 quarters · filed 2021-11-09 | $8.93M 10-Q · filed 2021-11-09 | $11.73M derived: sum of 4 quarters · filed 2022-03-08 | ||||
| 2020-06-30 | $2.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $5.94M 10-Q · filed 2021-08-06 | $8.74M derived: sum of 3 quarters · filed 2022-03-08 | $11.54M derived: sum of 4 quarters · filed 2022-03-08 | ||||
| 2020-03-31 | $2.97M 10-Q · filed 2021-05-07 | $5.77M derived: sum of 2 quarters · filed 2022-03-08 | $8.57M derived: sum of 3 quarters · filed 2022-03-08 | $11.37M derived: sum of 4 quarters · filed 2022-03-08 | ||||
| 2019-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $5.60M derived: sum of 2 quarters · filed 2022-03-08 | $8.40M derived: sum of 3 quarters · filed 2022-03-08 | $11.20M 10-K · filed 2022-03-08 | ||||
| 2019-09-30 | $2.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $5.60M derived: sum of 2 quarters · filed 2020-11-09 | $8.40M 10-Q · filed 2020-11-09 | $11.20M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | $2.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $5.60M 10-Q · filed 2020-08-07 | $8.40M derived: sum of 3 quarters · filed 2021-02-25 | $11.50M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | $2.80M 10-Q · filed 2020-05-11 | $5.60M derived: sum of 2 quarters · filed 2021-02-25 | $8.70M derived: sum of 3 quarters · filed 2021-02-25 | $11.50M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $5.90M derived: sum of 2 quarters · filed 2021-02-25 | $8.70M derived: sum of 3 quarters · filed 2021-02-25 | $11.20M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $3.10M 10-Q · filed 2018-11-06 | $5.90M derived: sum of 2 quarters · filed 2019-08-07 | $8.40M 10-Q · filed 2019-11-08 | $9.30M 10-Q · filed 2018-11-06 | $10.60M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2018-06-30 | $2.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $5.60M 10-Q · filed 2019-08-07 | $7.50M derived: sum of 3 quarters · filed 2020-02-27 | $10.60M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-03-31 | $2.80M 10-Q · filed 2019-05-07 | $4.70M derived: sum of 2 quarters · filed 2020-02-27 | $7.80M derived: sum of 3 quarters · filed 2020-02-27 | $10.60M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2017-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $5.00M derived: sum of 2 quarters · filed 2020-02-27 | $7.80M derived: sum of 3 quarters · filed 2020-02-27 | $11.20M 10-K · filed 2020-02-27 | ||||
| 2017-09-30 | $3.10M 10-Q · filed 2018-11-06 | $5.90M derived: sum of 2 quarters · filed 2018-11-06 | $9.30M 10-Q · filed 2018-11-06 | $8.40M 10-Q · filed 2017-11-07 | $11.50M derived: sum of 4 quarters · filed 2019-03-18 | |||
| 2017-06-30 | $2.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $5.60M 10-Q · filed 2018-08-08 | $8.40M derived: sum of 3 quarters · filed 2019-03-18 | $11.20M derived: sum of 4 quarters · filed 2019-03-18 | ||||
| 2017-03-31 | $2.80M 10-Q · filed 2018-05-08 | $5.60M derived: sum of 2 quarters · filed 2019-03-18 | $8.40M derived: sum of 3 quarters · filed 2019-03-18 | $11.20M derived: sum of 4 quarters · filed 2019-03-18 | ||||
| 2016-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $5.60M derived: sum of 2 quarters · filed 2019-03-18 | $8.40M derived: sum of 3 quarters · filed 2019-03-18 | $11.20M 10-K · filed 2019-03-18 | ||||
| 2016-09-30 | $2.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $5.60M derived: sum of 2 quarters · filed 2017-11-07 | $8.40M 10-Q · filed 2017-11-07 | $11.20M derived: sum of 4 quarters · filed 2018-03-08 | ||||
| 2016-06-30 | $2.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $5.60M 10-Q · filed 2017-08-08 | $8.40M derived: sum of 3 quarters · filed 2018-03-08 | $11.20M derived: sum of 4 quarters · filed 2018-03-08 | ||||
| 2016-03-31 | $2.80M 10-Q · filed 2017-05-09 | $5.60M derived: sum of 2 quarters · filed 2018-03-08 | $8.40M derived: sum of 3 quarters · filed 2018-03-08 | $11.20M derived: sum of 4 quarters · filed 2018-03-08 | ||||
| 2015-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $5.60M derived: sum of 2 quarters · filed 2018-03-08 | $8.40M derived: sum of 3 quarters · filed 2018-03-08 | $11.20M 10-K · filed 2018-03-08 | ||||
| 2015-09-30 | $2.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $5.60M derived: sum of 2 quarters · filed 2016-11-09 | $8.40M 10-Q · filed 2016-11-09 | $11.20M derived: sum of 4 quarters · filed 2017-03-03 | ||||
| 2015-06-30 | $2.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $5.60M 10-Q · filed 2016-08-09 | $8.40M derived: sum of 3 quarters · filed 2017-03-03 | $11.20M derived: sum of 4 quarters · filed 2017-03-03 | ||||
| 2015-03-31 | $2.80M 10-Q · filed 2016-05-09 | $5.60M derived: sum of 2 quarters · filed 2017-03-03 | $8.40M derived: sum of 3 quarters · filed 2017-03-03 | $11.20M derived: sum of 4 quarters · filed 2017-03-03 | ||||
| 2014-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-03 | $5.60M derived: sum of 2 quarters · filed 2017-03-03 | $8.40M derived: sum of 3 quarters · filed 2017-03-03 | $9.80M 10-K · filed 2017-03-03 | ||||
| 2014-09-30 | $2.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $5.60M derived: sum of 2 quarters · filed 2015-11-09 | $7.00M 10-Q · filed 2015-11-09 | $7.00M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-06-30 | $2.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $4.20M 10-Q · filed 2015-08-10 | $4.20M derived: sum of 3 quarters · filed 2016-02-29 | $4.20M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-03-31 | $1.40M 10-Q · filed 2015-05-11 | $1.40M derived: sum of 2 quarters · filed 2016-02-29 | $1.40M derived: sum of 3 quarters · filed 2016-02-29 | $1.40M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $0.00 derived: sum of 2 quarters · filed 2016-02-29 | $0.00 derived: sum of 3 quarters · filed 2016-02-29 | $0.00 10-K · filed 2016-02-29 | ||||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $0.00 derived: sum of 2 quarters · filed 2014-11-06 | $0.00 10-Q · filed 2014-11-06 | |||||
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-04 | $0.00 10-Q · filed 2014-08-04 | ||||||
| 2013-03-31 | $0.00 10-Q · filed 2014-05-12 | |||||||
| 2012-12-31 | $0.00 10-K · filed 2015-02-26 | $500.00K 10-K · filed 2013-03-12 | ||||||
| 2011-12-31 | $300.00K 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |